Actively Recruiting
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
Led by Eugene F Yen, MD · Updated on 2021-04-15
10
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
CONDITIONS
Official Title
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of collagenous colitis or lymphocytic colitis confirmed by colon biopsies reviewed by two pathologists
- Collagenous colitis defined by a collagenous subepithelial table thicker than 10 micrometers with specific inflammation and epithelial changes
- Lymphocytic colitis defined by more than 20 intraepithelial lymphocytes per 100 epithelial cells with specific inflammation and epithelial changes
- Active flare with more than 3 watery or loose stools per day on more than 4 days out of 7 over more than 4 weeks within the past 3 months
You will not qualify if you...
- No specific exclusion criteria listed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NorthShore University HealthSystem
Evanston, Illinois, United States, 60201
Actively Recruiting
Research Team
D
Daniel Amusin, BS
CONTACT
I
Iris Chiou, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here